PSMA PET

DIAGNOSTIC_TEST5 trials

Sponsors

H. Lee Moffitt Cancer Center and Research Institute, Xijing Hospital, Jules Bordet Institute, General University Hospital, Prague

Conditions

High Risk Prostate CancerLesion PI-RADS 3MetastasesMultiparametric MRIPSMA PETPSMA-PETProstate CancerProstatic Neoplasms

Phase 2

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores

RecruitingNCT03495427

H. Lee Moffitt Cancer Center and Research InstituteProstate Cancer, Recurrent Prostate Cancer

Start: 2019-12-18End: 2029-05-01Target: 60Updated: 2026-03-02

Unknown Phase

68Ga-PSMA PET in the Prostate Cancer

RecruitingNCT04967001

Xijing HospitalMetastases, Prostatic Neoplasms, PSMA-PET

Start: 2021-06-01End: 2024-12-31Target: 300Updated: 2024-01-25

68Ga-PSMA PET in the Renal Cell Carcinoma

RecruitingNCT04987086

Xijing HospitalMetastases, PSMA PET, Renal Cancer

Start: 2021-06-01End: 2027-12-01Target: 300Updated: 2026-03-11

The Added-value of PSMA PET in Detecting Clinically Significant Prostate Cancer Lesions in Patients Undergoing MRI-targeted Biopsy. (PANDORA)

RecruitingNCT06867588

Jules Bordet InstituteLesion PI-RADS 3, Multiparametric MRI

Start: 2024-10-17End: 2026-12-31Target: 68Updated: 2025-03-31

Predictors of Nodal and Distant Metastatic Disease Detected by PSMA PET in Treatment-Naïve High-Risk Prostate Cancer: A Czech Multicentre Cohort Study

Active, not recruitingNCT07608419

General University Hospital, PragueHigh Risk Prostate Cancer, Prostate Cancer, PSMA PET +1

Start: 2016-01-01End: 2027-12-01Target: 400Updated: 2026-05-27